Crit Care Med. 2018 Sep 14. doi: 10.1097/CCM.0000000000003405. [Epub ahead of print]
Parekh D1,2,3, Dancer RCA1,4, Scott A1, D'Souza VK1, Howells PA1, Mahida RY1, Tang JCY5, Cooper MS6, Fraser WD5, Tan L7, Gao F1,4, Martineau AR 8, Tucker O1,4, Perkins GD3,4, Thickett DR1,2.
- Esophageal Cancer 40 percent less likely in parts of UK with more sun (vitamin D) – Feb 2018
- 2X more likely to survive a form of esophageal cancer in China if have good vitamin D receptor – Feb 2017
Cancer category starts with the following
198 items Overview Cancer and vitamin D
- After Cancer Diagnosis
- Bladder Cancer
- Breast Cancer
210 items Overview Breast Cancer and Vitamin D
- Colon Cancer
103 items Overview Cancer-Colon and vitamin D
- Lung Cancer
45 items Overview Lung cancer and vitamin D
- Lymphoma Cancer
- Other Cancer
- Prostate Cancer
86 items Prostate Cancer and Vitamin D studies
- Pancreatic Cancer
- Skin Cancer
104 items Overview Suntans melanoma and vitamin D
- Evidence that Vitamin D prevents Cancer – Grant Feb 2018
- Cancer risk in older women reduced 32 percent by 2,000 IU of Vitamin D plus Calcium – 4 year RCT Oct 2016
- Vitamin D prevents breast cancer, reduces BC mortality, and reduces BC chemotherapy problems – Sept 2018
- Breast Cancer Mortality reduced 60 percent if more than 60 ng of Vitamin D – meta-analysis June 2017
- Diagnosed with breast cancer – take vitamin D to cut chance of death by half – July 2018
- Pancreatic cancer 55 percent less likely if optimal vitamin D (vs low) – Nov 2017
- Melanoma 25 X more likely if low vitamin D – Feb 2018
- Cancer survival 4 percent more likely with just a little more vitamin D (4 ng) - meta-analysis July 2014
- Cancer treatment by Vitamin D sometimes is restricted by genes – Oct 2018
- Risk of Cancer increased due to Vitamin D Receptor – meta-analysis of 73 studies Jan 2016
- Cancer not treated by Vitamin D when ignore dose size, type, and length of trial – meta-analysis April 2018
Overview Loading of vitamin D contains the following
If a person is, or is suspected to be, very vitamin D deficient a loading dose is typically given
- Loading = repletion = quick replacement (previously known as Stoss)
- Loading doses range in size from 100,000 IU to 1,000,000 IU of Vitamin D3
- The size of the loading dose is a function of body weight - see below
Unfortunately, some doctors persist in using Vitamin D2 instead of D3
- Loading may be done as quickly as a single day, to as slowly as 3 months.
It appears that spreading the loading dose over 4-20 days is a good compromise
- Loading is typically oral, but sometimes by injection (I.M,)
- The loading dose persists in the body for about 3 months
The loading dose should be followed up with continuing maintenance
Unfortunately, many doctors fail to follow-up with the maintenance dosing.
- As about 1 in 300 people have some form of mild allergic reaction to vitamin D supplements,
it appears prudent to test with a small amount of vitamin D before giving a loading dose
- The causes of a mild allergic reaction appear to be: (in order of occurance)
1) lack of magnesium - which can be easily added
2) allergy to capsule contents - oil, additives (powder does not appear to cause any reaction)
3) allergy to the tiny amount of D3 itself (allergy to wool) ( alternate: D3 made from plants )
133 studies at VitaminDWiki
Trauma and surgery category starts with the followingTrauma and Surgery category has
see also Concussions
Overview Fractures and Falls and Vitamin D
Cancer - After diagnosis chemotherapy
Search VitaminDWiki for TBI OR "Traumatic Brain Injury" 690 items as of May 2019
Search VitaminDWiki for cathelecidin OR hCAP18 187 items as of May 2019
Search VitaminDWiki for ICU OR “critical care” OR “intensive care” OR “acute care”
1740 items as of May 2019
Search VitaminDWiki for transplant 794 items as of Jan 2018
Observational studies suggest an association between vitamin D deficiency and adverse outcomes of critical illness and identify it as a potential risk factor for the development of lung injury. To determine whether preoperative administration of oral high-dose cholecalciferol ameliorates early acute lung injury postoperatively in adults undergoing elective esophagectomy.
DESIGN: A double-blind, randomized, placebo-controlled trial.
SETTING: Three large U.K. university hospitals.
PATIENTS: Seventy-nine adult patients undergoing elective esophagectomy were randomized.
INTERVENTIONS: A single oral preoperative (3-14 d) dose of 7.5 mg (300,000 IU; 15 mL) cholecalciferol or matched placebo.
MEASUREMENTS AND MAIN RESULTS:
Primary outcome was change in extravascular lung water index at the end of esophagectomy.
Secondary outcomes included
- PaO2:FIO2 ratio,
- development of lung injury,
- ventilator and organ-failure free days,
- 28 and 90 day survival,
- safety of cholecalciferol supplementation,
- plasma vitamin D status (25(OH)D, 1,25(OH)2D, and vitamin D-binding protein),
- pulmonary vascular permeability index, and
- extravascular lung water index day 1 postoperatively.
An exploratory study measured biomarkers of alveolar-capillary inflammation and injury.
Forty patients were randomized to cholecalciferol and 39 to placebo. There was no significant change in extravascular lung water index at the end of the operation between treatment groups (placebo median 1.0 [interquartile range, 0.4-1.8] vs cholecalciferol median 0.4 mL/kg [interquartile range, 0.4-1.2 mL/kg]; p = 0.059).
Median pulmonary vascular permeability index values were significantly lower in the cholecalciferol treatment group (placebo 0.4 [interquartile range, 0-0.7] vs cholecalciferol 0.1 [interquartile range, -0.15 to -0.35]; p = 0.027).
Cholecalciferol treatment effectively increased 25(OH)D concentrations, but surgery resulted in a decrease in 25(OH)D concentrations at day 3 in both arms. There was no difference in clinical outcomes.
High-dose preoperative treatment with oral cholecalciferol was effective at increasing 25(OH)D concentrations and reduced changes in postoperative pulmonary vascular permeability index, but not extravascular lung water index.
This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
(No PDF as of Sept 18, 2018)
- After Cancer Diagnosis